与TNF-α抑制剂相关的血栓性不良事件:FAERS数据库的现实世界药监测分析
Lijuan Song1, Nan Yang2, Xinglong Xing3
1Department of General Surgery, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
瘤亡因子-α (TNF-α) 阻断剂与血栓事件有关. 风险因患者组和治疗阶段而异,需要仔细监测凝血指标以提高安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 药物监督 药物监督 药物监督
- 心血管医学 心血管医学
背景情况:
- 瘤亡因子-α (TNF-α) 抑制剂广泛用于炎症状况.
- 与TNF-α抑制剂相关的潜在血栓性不良事件需要彻底调查.
研究的目的:
- 探索TNF-α抑制剂药物与血栓性不良事件之间的关联.
- 分析不同TNF-α抑制剂药物和患者人口统计数据中的血栓形成风险信号.
主要方法:
- 利用了2004-2024年FDA不良事件报告系统 (FAERS) 的数据.
- 雇员不成比例分析,子组分析 (年龄,性别),诱导时间和韦布尔分布.
主要成果:
- 对所有五种TNF-α抑制剂药物检测到与血栓相关的不良事件信号.
- 阿达利穆马布显示出产后血栓形成的最强信号;脉血栓形成的信号最弱.
- 性别分组分析揭示了在总人口中未见的特定不良事件信号.
结论:
- TNF-α抑制剂与多种类型的血栓性不良事件有关,患者组和治疗持续时间的风险各不相同.
- 临床实践应包括个性化的血栓形成风险评估和对凝血参数的警监测.
- 这些发现为优化TNF-α抑制剂治疗和提高患者安全提供了洞察力.
更多相关视频
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
11:18Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
Published on: April 2, 2013
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
